Objective To assess the evidence regarding the effect of time of gluten introduction and breastfeeding on the risk of developing celiac disease (CD).
Conclusion
There is currently no evidence to support that early introduction of gluten to the infant diet increases the risk of CD; however, late introduction of gluten may be associated with increased risk of CD. More studies are needed that control for potential confounders and that evaluate environmental factors in low-risk families. (J Pediatr 2016; 168:132-43) .
C eliac disease (CD) is an autoimmune disorder triggered by gluten in genetically susceptible individuals. In CD, gluten induces a chronic inflammatory response that progressively leads to small intestinal atrophy. 1 Not everyone with genetic predisposition will develop CD; thus, additional environmental risk factors, such as the way in which gluten is introduced to infant's diet, have been proposed. 2 This has impacted European feeding recommendations, although evidence-based recommendations are scarce. [1] [2] [3] [4] [5] The Nutrition Committee of the European Society of Paediatric Gastroenterology, Hepatology, and Nutrition has recommended avoiding the introduction of gluten before age 4 months and after age 7 months. 6 Thus, the ideal time for introducing gluten to the diet would fall between the fourth and sixth months of life, when gluten should be introduced in "small quantities" and progressively, while maintaining breastfeeding whenever possible. 7 The evidence for this came from 1 systematic review of the effect of gluten introduction on the risk of CD 8 ; however, owing to heterogeneity among studies, a summary estimate of risk was not provided. This is a rapidly changing field, with new epidemiologic data emerging regularly. Thus, we conducted an updated systematic review of randomized controlled trials (RCTs) and observational studies evaluating the current evidence regarding the possible relationship between the timing and quantity of gluten introduction, breastfeeding, and the risk of developing CD. We hypothesized that the data could be synthesized as a meta-analysis to provide a risk estimate for the development of CD.
Methods
We included studies evaluating the introduction of gluten in infants in whom the development of CD was assessed. CD diagnosis used any well-defined criteria available (duodenal biopsy-and/or serology-compatible and HLA DQ2/8-positive, when performed) or at risk for CD (positive HLA DQ2/8, first-degree relative with CD or type 1 diabetes). Controls included infants in which CD diagnosis was not established or CD was excluded by duodenal biopsy or specific serology (tissue transglutaminase antibody, anti-endomysium antibody, or deaminated peptide gliadin).
The following intervention and control groups were eligible according to the research question they were answering. For timing of gluten introduction, the intervention group included any gluten-containing product (eg, cereals, flour or any other foods containing gluten, preparations manufactured for research purposes) introduced early (<4 months) or late (>7 months) and the control group included gluten introduced between 4-6 months of age. For gluten dose and mode of introduction, the intervention group was considered as a large amount of gluten introduced in the diet and control group a standard amount as defined by the authors. The mode of introduction of gluten was considered "gradual" in the intervention group and "usual" in the control group, as defined by the authors. We considered the intervention group to be breastfed for any duration and the control group to not have had any breastfeeding. An alternative definition was an intervention group that was breastfed vs a control group that was not breastfed during weaning. The primary outcome was to assess systematically the development of CD autoimmunity (tissue transglutaminase antibody or anti-endomysium antibody) and/or biopsy.
We included observational studies (cohort or case-control studies) and randomized, double-blind, placebo-controlled trials (RCTs) up to January 2014. We considered cross-over studies only if the results were available before the crossover, so the study could be evaluated as a parallel group. Publications were considered regardless of language and publication status. Abstracts were included only if we were able to obtain further details from the investigators. Only studies performed in a pediatric population with CD defined according to compatible biopsy and/or serology and an eligible non-CD control group were considered. If information was missing from a study, the authors were contacted to provide details. Studies were excluded if they were case reports or case series, if CD was not confirmed by serology or biopsy, if there was no non-CD control group, or if reported in duplicate publications. The search strategy is outlined in Appendices 1-4 (available at www.jpeds.com).
Two authors screened the titles and abstracts to ensure that we captured all eligible studies. A list of studies to include for assessment of eligibility was created, and duplicate studies were removed at this initial stage. To ensure that inclusion and exclusion criteria were rigorously interpreted, full-text screening was performed by 2 blinded reviewers. For publications in a language other than English, a translator with expertise in the field was provided with specific instructions for the screening process for 8 studies. Data related to the full-text screening were collected in Excel (Microsoft, Redmond, Washington), and results were compared. Agreement was calculated after full-text screening by using kappa statistics (GraphPad Software, La Jolla, California) for categorical data and raw agreement for continuous data. Raw agreement was reported in percentage, and kappa as fair agreement (k = 0.4-0.59), good agreement (k = 0.6-0.74), or excellent agreement (k $ 0.75). In cases of disagreement, the study was discussed, and if inclusion remained unresolved, a third party with experience in the topic and systematic reviews adjudicated. All of these steps were properly documented, and a table of excluded studies was created. The previous 2 reviewers extracted the data independently. A data extraction form was developed to collect detailed information regarding study design, population, intervention, controls, and outcomes, in addition to the information provided by the screening form. Patient demographic data, treatment, outcomes, and adverse events were recorded as mean AE SD, n/N, or % as applicable. Information to identify possible risk of bias was also collected on this form. The first author (M.P.) entered the information into RevMan 5.3 9 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen) for further analysis, and a second author checked for the consistency of data entry in this step.
Two authors independently assessed the risk of bias for each study using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions. 10 The risk of bias for RCTs was assessed according to the following domains: (1) random sequence generation; (2) allocation concealment; (3) blinding of participants and personnel; (4) blinding of outcome assessment; (5) incomplete outcome data; (6) selective outcome reporting; and (7) other bias. The NewcastleOttawa scale was used to assess quality from observational studies. 11 Evidence was graded according to study design, consistency, directness, imprecision, and reporting bias. Considering the lack of evidence of adequacy of follow-up in cohort studies, we used a cutoff of 3 years based on results from a large study in which >80% of patients with CD were diagnosed within the first 2 years. 4 To explore the possibility of risk of publication bias, a funnel plot and statistical tests for asymmetry were evaluated if there were more than 10 studies in the meta-analysis. 12 
Measures of Treatment Effect
Information regarding follow-up of the study population (patients enrolled and treated) was reported as total N, and data collected were reported as number of patients over the total number of patients for each arm (n/N). The total numbers of patients who did and did not develop CD in each arm at each time point were reported as number over the total sample population (n/N) in each arm. RCTs and cohort studies were summarized with risk ratio (RR) and case-control studies were summarized with OR, all with 95% CI. For quantitative analysis, a meta-analysis was performed when appropriate, using RevMan 5.3. 9 Data were pooled using a random-effects model. 10 Statistically significant heterogeneity was assessed using both the I 2 statistic and the c 2 test. A value of 0% for I 2 indicates no observed heterogeneity, and larger values denote heterogeneity. Significant heterogeneity was considered at an I 2 >25% or a c 2 P value of <.10.
Subgroup analyses were performed considering the risk of CD on the following: (1) amount of gluten introduced; (2) gradual (2-3 g/100 g food) vs sudden gluten introduction; and (3) studies conducted in North America vs other countries. Sensitivity analyses were planned to address questions Volume 168 January 2016 on early (<2-4 months) vs late (>6-7 months) gluten introduction or to evaluate the effect of specific studies.
The current systematic review and meta-analysis were performed according the recommended Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement (http://www.prisma-statement.org/statement.htm).
Results
We identified a total of 1982 studies, of which 1789 remained after removing duplicates. Twenty-six additional studies were identified by a recursive bibliography search from the identified papers. Of these studies, 1900 were excluded at the title screening stage, and 108 were excluded at the abstract screening stage; 45 studies were eligible for full-text screening ( Figure 1 ; available at www.jpeds.com). Good interreviewer agreement was found at the title and abstract screening stages (k = 0.60; SE of k = 0.108; 95% CI, 0.39-0.81) and moderate in the full-text screening (k = 0.43; SE of k = 0.083; 95% CI, 0.270-0.595). After full-text review, 28 studies were excluded. The results from ongoing investigations were not published until the analysis of 5 studies identified in abstract format or clinical trials website. [13] [14] [15] [16] [17] Authors of these studies were contacted; however, none of the authors was able to provide additional information. Seventeen studies finally met the inclusion and exclusion criteria for quantitative and qualitative synthesis, and data were extracted. The characteristics of these 17 included studies are summarized in Table I .
Timing of Gluten Introduction
Fifteen studies [2] [3] [4] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] met the inclusion criteria and evaluated the risk of CD at different time points of gluten introduction. These included 2 RCTs 18,19 and 13 [2] [3] [4] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] observational studies.
Introduction of Gluten at 6 Months vs 12 Months
Two RCTs 18, 19 evaluated gluten introduction at 5-6 months vs 12 months; together, these trials reported 18 events in 183 patients. There was no statistically significant increased risk of CD associated with the "standard" gluten introduction (5-6 months) compared with "late" gluten introduction (12 months) (RR, 1.41; 95% CI, 0.59-3.39). No heterogeneity was observed between the studies (I 2 = 0%), although the number of events was modest. A sensitivity analysis was performed with results from a follow-up of the study from Sellito et al 18 that were provided by the authors, and the results remained unchanged. The risk of bias was assessed, and a high risk of bias owing to blinding and a high rate of noncompliance (30%) was identified for one study, 19 and a high risk of selection bias owing to an imbalance of dropouts in the study groups and unclear for randomization and allocation concealment were identified for the other study. 18 Forest plots of RCTs used in the meta-analysis and risk of bias tool are shown in Figure 2 , A.
Introduction of Gluten at <4 Months vs the Recommended Time (4-6 Months) or Later (>6 Months) Four cohort studies 2, 3, 20, 21 compared early (<4 months) vs late (>6 months) gluten introduction involving a total of 50 451 children and 282 events. The pooled analysis for early gluten introduction compared with late gluten introduction from these observational studies revealed no differences in the risk of CD (RR, 1.08; 95% CI, 0.76-1.54; P = .68), with no significant heterogeneity between studies (I 2 = 0%) (Figure 2 , B). The same 4 cohort studies 2,3,20,21 also compared early (<4 months) and recommended gluten introduction (4-6 months), and found no significant difference in the risk of CD (RR, 1.27; 95% CI, 0.86-1.86; P = .38), with no significant heterogeneity (I 2 = 3%) ( Figure 2 , C). One case control study 4 that evaluated introduction of gluten in 491 children with CD and 781 controls without known CD found no difference in gluten introduction at 1-4 months vs 5-12 months for CD cases vs controls (OR, 0.70; 95% CI, 0.48-1.03; P = .07).
Introduction of Gluten at the Recommended Time (4-6 Months) vs Later (>6 Months)
Five cohort studies 2,3,20-23 compared the recommended time for gluten introduction (4-6 months) vs later introduction. A meta-analysis of these studies demonstrated a 25% increase in the risk of CD in the population with late gluten introduction compared with the population with the recommended introduction (RR, 1.25; 95% CI, 1.08-1.45; P = .002) (Figure 2, D) . The sensitivity analysis with sequential removal of any individual study did not influence the results, except for the removal of 1 study 22 in which the pooled data became marginally significant (RR, 1.21; 95% CI, 0.97-1.50; P = .09). One case-control study 4 evaluated introduction of gluten in 491 children with CD and 781 controls without known CD. In contrast to the cohort data, this study found that CD cases were more likely to have gluten introduced at 1-6 months compared with 7-12 months (OR, 1.42; 95% CI, 1.01-2.00; P = .04). There was, however, no association between the time of gluten introduction and the risk of CD in a multivariate analysis that controlled for breastfeeding during weaning, amount of flour introduced, and type of food given when flour was introduced. 4 
Introduction of Gluten at Other Time Points
Other studies evaluated the risk of early vs late gluten introduction on the risk of CD; however, these studies used different definitions for timing, and thus were not included in the meta-analysis. For example, Peters et al 23 reported that the age of gluten introduction (<3 months vs >3 months) had no influence on the incidence of CD (OR, 0.72; 95% CI, 0.29-1.79). A similar definition for gluten introduction was used by Auricchio et al 24 evaluating 216 children with CD and their healthy siblings, who reported that early introduction of gluten was not associated with increased risk of CD. A risk of bias related to the design was identified in that study, however. Similar findings were reported by Greco et al, 25 who considered a lower cutoff of 2 months for the differentiation of early and late gluten introduction.
Time to Introduction of Gluten and Risk of CD
Four studies 23, [26] [27] [28] reported continuous data on the time of gluten introduction in a total of 240 patients with CD compared with 534 controls. Each study found no statistically significant difference in the time of gluten introduction and odds of CD. We assumed that the median values given in 3 of those reports [26] [27] [28] were similar to the mean, and estimated the SD from the ranges given. Pooling the studies also revealed no statistically significant difference in mean difference in months of gluten introduction (mean difference, À0.10; 95% CI, À0.27 to 0.07), with little heterogeneity among the studies (I 2 = 12%) (Figure 2 , E).
Gluten Dose and Mode of Introduction
Four studies 2,4,22,28 evaluated the amount of gluten introduced and the effect on CD risk; however, differences in the definition on amount on gluten considered by each group precluded pooling of the data from these studies. Ivarsson et al 4 reported that larger amounts of gluten at the time of first introduction (16 g) increased the risk of CD (OR, large vs small or medium amounts, 1.9; 95% CI, 1.4-2.6). A recent ecological study by the same group 22 comparing 2 populations born in 1993 and 1997 found that the population with the lower risk for CD (born in 1997) ingested significantly less gluten containing cereal compared with the population with the greater risk, that born in 1993 (24 g/day vs 38 g/day). Norris et al 2 proposed that greater amounts of gluten introduced at 7 months could be associated with increased risk of CD compared with the amount of gluten introduced at 4 months; however, the exact amounts of gluten consumed were not specified. In contrast, another study 28 found similar consumption of wheat at the time of diagnosis in patients with CD and in controls; however, that study evaluated the amount of gluten consumed at the moment of the biopsy for CD diagnosis, but not during weaning.
Breastfeeding at the Time of Gluten Introduction and Risk of CD Three cohort studies evaluated the association between breastfeeding and CD; however, different outcomes were reported by each study, and meta-analysis was not possible. Stordal et al 20 reported an increased risk of CD in infants breastfed for >12 months compared with those breastfed for <6 months (aOR, 1.49; 95% CI, 1.01-2.21; P = .04). The authors found no difference in CD risk between children breastfed for >1 month and those breastfed for <1 month during weaning (RR, 1.04; 95% CI, 0.66-1.03). Norris 24, 25 reported that patients with CD were less likely to have been breastfed compared with those without CD, whereas the other 3 studies 26, 30, 31 found no statistically significant association between breastfeeding and CD. Overall, 433 of 851 patients with CD (51%) were breastfed, compared with 119 034 of 171 160 controls (70%). The meta-analysis showed a nonsignificant trend toward lower odds of breastfeeding in the CD group (OR, 0.55; 95% CI, 0.28-1.10; P = .09) (Figure 2, F) . There was a high degree of heterogeneity (I 2 = 92%) among the studies, but there were too few studies to enable an adequate exploration of the reasons for this.
Six studies, 2, 4, 20, 23, 27, 28 with a total of 48 845 participants, including 926 patients with CD, evaluated whether participants were breastfed at weaning. Three of these studies 4, 23, 27 reported that patients with CD were less likely to have been breastfed during weaning compared with those without CD, whereas the other 3 studies found no difference between the 2 groups. 2, 20, 28 Overall 479 of 926 patients with CD (52%) were breastfed during weaning, compared with 40 789 of 47 919 controls (85%). The meta-analysis showed a nonsignificant trend toward lower odds of breastfeeding in the CD group (OR, 0.70; 95% CI, 0.45-1.10; P = .12) (Figure 2, G) . There was a high degree of heterogeneity (I 2 = 78%) among the studies, but there were too few studies for an adequate exploration of this. 
Discussion
CD is a common and serious disease, and parents need advice on the best approach to introducing gluten into their child's diet. Breastfeeding is beneficial in many ways, but whether it also helps reduce the risk of CD is unclear. It has been hypothesized that early introduction of gluten, usually defined as before 4 months of age, may increase the risk of CD, 20, [30] [31] [32] and that breastfeeding may be protective, particularly at the time of gluten introduction. In addition, a high gluten content at the time of introduction has been suggested as another important risk factor. These issues were addressed in a previous systematic review, 8 but evidence was not conclusive. We have updated that review with additional evidence, and have also synthesized the data in an attempt to provide a clearer evidence base.
Our review included 5 studies of children at increased risk (family members of those with CD or diabetes mellitus, or HLA-compatible), 2, 18, 19, 21, 28 and 12 studies of children at general risk. 3, 4, 20, [22] [23] [24] [25] [26] [27] [29] [30] [31] Our results indicate that late introduction of gluten to the infant diet may increase the risk of CD compared with introduction at age 4-6 months. Our best estimate of the increase in risk is 25%, which is statistically significant. The data related to the amount of gluten introduced are scarce, but large amounts of gluten started at weaning could be associated with an increased risk of developing CD. These data are not robust, and it is particularly difficult to evaluate the role of confounding factors in these associations. Studies included in this review rarely controlled for all possible confounding factors, such as breastfeeding, type and amount of gluten ingested, and other feeding patterns; thus, it is therefore possible that the associations identified are related to other factors in the early upbringing of children.
After this meta-analysis was concluded, 2 relevant RCTs including data from almost 1000 children each, 33, 34 and an additional prospective birth cohort study, 35 were published. Although we could not include these studies in our present analysis, we believe it necessary to summarize their main conclusions and also to base our final recommendations on all of the analytically reviewed papers and these 3 newly published ones as well.
The first study, by Vrezinga et al, 33 was a multicenter, randomized, double-blind, placebo-controlled dietary intervention study involving 944 children who had at least 1 firstdegree relative with CD and had an HLA status compatible with CD. From age 4 to 6 months, 475 participants received 100 mg of vital gluten daily, and 469 received placebo. After 24 weeks, intake of gluten was liberalized in both groups. CD serology was measured periodically. The study found no significant between-group difference in the risk of CD after 3 years. The presence of a placebo control removes the possibility of bias, and the randomized design reduces the possibility of confounding; however, this does not completely resolve all questions. This trial evaluated only children at high risk for CD, and the results might not apply to those at average risk. Furthermore, a significant proportion was lost to follow-up, and another 10% did not adhere to the recommended diet. 33 Regarding this latter point, it is also impossible to accurately determine the dietary intake of infants, and it is possible that some participants in the placebo group may have ingested gluten at 4-6 months, which contaminates the results. Finally, whether 100 mg is the optimal amount of gluten to introduce at age 4 months is unclear. It is also possible that a greater amount or a gradually increasing amount starting at 4 months may be needed as "protective." To emphasize this uncertainty, we included this randomized trial in our systematic review as a post hoc analysis (because it is outside the time period of our search) using a randomeffects model, and found no differences in results (RR, 1.19; 95% CI, 0.99-1.43; P = .06).
In a large multicenter Italian study reported by Lionetti et al, 34 832 newborns with a first-degree relative with CD and a determined HLA genotype were randomized to introduction of dietary gluten at age 6 or at 12 months. There was a delay in the development of CD by age 2 years in those introduced to gluten at 12 months, but no difference between the 2 groups at age 5 years. This trial did not directly address the question regarding the amount of gluten at the time of introduction. 34 Aronsson et al 35 analyzed dietary risk factors for the development of CD autoimmunity in a multinational birth cohort study of 6436 children at risk for the development of CD. They found no associated increased risk of CD autoimmunity with early or late feeding of gluten compared with the reference group with gluten introduction at age 4-6 months.
Based on the foregoing studies, early-life gluten feeding practice does not seem to influence CD risk in children at genetic risk. Moreover, the results of this meta-analysis support only a moderate increase in risk with late, but not early, gluten introduction. The question of gluten dose as a risk factor remains unresolved, however. Furthermore, a recently published meta-analysis with similar objectives, methodology, and results as our present analysis 36 included 2 of the most recent 2 RCTs, 33, 34 but failed to identify 2 large earlier studies 26, 29 that were included in our analysis. Therefore, our analysis complements that recently published meta-analysis.
Studies on breastfeeding have yielded conflicting results, with some suggesting that breastfeeding is protective 4, 27 and others finding an increased risk under certain conditions (eg, after 12 months) 20 or no association. 2 Our meta-analysis suggests a nonsignificant trend toward a benefit of breastfeeding and shows similarities with the 2 recent large studies that did not find any association between breastfeeding and risk of CD. 33, 34 However, when those 2 studies were added in a post hoc analysis, 1 study 33 provided data for the analysis on breastfeeding vs no breastfeeding, and there remained a nonsignificant trend toward a benefit of breastfeeding (OR, 0.60; 95% CI, 0.33-1.10; P = .10), whereas the other study 34 provided data on breastfeeding during weaning, and again this did not change the conclusions of our review (OR, 0.74; 95% CI, 0.50-1.11, P = .15). Overall, these trends are insufficient to allow any conclusions regarding breastfeeding and the risk of CD.
One challenge in synthesizing this literature lies in how breastfeeding is defined. We took the approach of defining this as breastfed vs not breastfed, or not breastfed at the time of weaning. Even though we tended to homogenize the characterization of breastfeeding, as explained in the Methods section, there is substantial heterogeneity in the definition. For example, there is the issue of exclusive breastfeeding vs some breastfeeding supplemented by bottle feeding, an issue not addressed in this systematic review. Another challenge is again this issue of confounding factors. Although some positive studies 4 adjusted for potential confounders, others 27 did not. Finally, we acknowledge our disappointment that the data are not sufficiently robust to allow definitive evidence-based recommendations for infant feeding to prevent CD. Additional studies 34, 35 published since the completion of our systematic review did not help in this regard. Those studies were performed in high-risk families, and the results might not apply to the general population; thus, future studies that include infants at lower genetic risk for CD are desirable. Nonetheless, even in the absence of solid evidence, it is important to reach a consensus for common practice guidelines, in particular taking into account the fact that the recent studies considered a specific population at high risk for CD, and whether the results apply to the general population is unclear. We believe that breastfeeding is the natural and preferred form of infant feeding, as supported by robust evidence and endorsed by major international bodies for a number of well-proven benefits outside of CD, including prevention of obesity. In regard to CD development, even without solid evidence of a protective effect of breastfeeding, we still support its use whenever possible in infants at risk for CD, in consideration of its general benefits. In this sense, we endorse the recommendation of the American Academy of Pediatrics to support exclusive breastfeeding for roughly the first 6 months of life. 37 As a corollary to this, we also feel it is now safe to assume that a short duration of breastfeeding, or introduction of gluten outside breastfeeding, carries no significant risk of later development of CD.
Overall, we can provide no solid recommendations regarding the most favorable timing for gluten introduction; however, based on our meta-analysis, the best time appears to be between 4 and 6 months. Another important point that remains unresolved is whether the amount of gluten introduced to infant diet influences CD risk. Future prospective studies evaluating the effect of gluten-free diet vs a normal diet or even the effect of a gluten overload on CD risk, as seen during the Swedish epidemic, 38 are needed as well. Unfortunately, given the lack of evidence on optimal amounts of gluten to introduce in infants born into families at risk for CD, for now this practice will remain based on expert opinion. Considering that infants ingest an average of $5 g of gluten daily between age 7 and 12 months, 39 it seems reasonable to introduce gluten in the amount of $1.2 g/ day at age 6 months and continue this dose for roughly 4 weeks, then increase the consumption to 2.5 g/day at 7-8 months and finally to $5 g/day up to age 12 months. After age 12 months, a full, "regular" amount of gluten might be acceptable; however, in a child at high risk for CD based on genetic determinations, the evidence suggests that limiting gluten quantity may delay the development of CD.
In conclusion, there is currently insufficient evidence supporting an association between early introduction of gluten to an infant's diet and increased risk of CD development. In contrast to a recent meta-analysis, the results from the present study suggest that late introduction of gluten may be associated with an increased risk of CD. In addition, the evidence is insufficient to determine whether breastfeeding has any affect on the risk of CD. There is a need for future large observational studies that carefully control for potential confounding factors and that evaluate these factors in both the general population and low-risk families. n Now 50 years later almost all of these analytes are still in clinical use; some have changed names, and other biomarkers have been discovered. We no longer use transaminase levels to diagnose myocardial infarction, but aldolase and creatine kinase remain the serum markers for muscle disease. Today, we have more accurate and time saving equipment for analysis and standardization of measurement units across laboratories, but normal values continue to be reported differently.
Serum enzyme measurements play a crucial role in modern medicine now as they did in 1966, and we rely now on these markers more than ever. Dr Howell points out that vitamin B6 deficiency leads to low levels of transaminases. Low serum concentration of alanine transaminase has recently been shown to be predictive of all-cause mortality in adults.
1 ALP is an enzyme that normally is higher in growing children; however, this continues to raise questions among clinicians about the potential for underlying liver disease. The availability to fractionate bone and liver derived ALP enzyme helps solve this question. Low levels, however, could indicate zinc deficiency, which might be ignored as all of us are accustomed to looking for elevation as marker of disease. Dr Howell's final comment remains true today: "there is no single change in serum enzyme which is absolutely specific for a given disease." We continue to aim for the development of a truly disease specific and sensitive biomarker. For children, this is especially needed as some of our diagnostic procedures may affect our patients in the long term (eg, the effect of general anesthesia on neurodevelopment). 
